Home←Clinical support←Prescribing guidelines←Diabetes: Prescribing of Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2 inhibitors) and risk of Diabetic Ketoacidosis (including in patients with COVID-19) (APC Approved)
Diabetes: Prescribing of Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2 inhibitors) and risk of Diabetic Ketoacidosis (including in patients with COVID-19) (APC Approved) prescribing guideline